Date: 2012-01-05
Type of information: Fundraising
Company: AMP Therapeutics (Germany)
Investors: Boehringer Ingelheim Venture Fund (Germany) - Novartis Venture Fund (Switzerland)
Amount: undisclosed
Funding type: series A financing round
Planned used: The funds will be used to advance AMPT\'s Gram-negative antibiotic program. It will also be used to enhance the company\'s R&D and to accelerate the development of its product pipeline, including lead compounds developed from insect peptides.
Others: The company was founded in 2009 as a spin-off from Ralf Hoffmann\'s laboratory at the university of Leipzig. It is based in the Center for Biotechnology and Biomediciine at BIO City in Leipzig. AMP Therapeutics is engaged in the discovery and commercialization of new medicine for the treatment of severe bacterial infections caused by drug-resistant Gram-negative bacteria. Its technology is based on naturally occuring antimicrobial peptides found around various species, including insect species.
Therapeutic area: Infectious diseases
